Such a test would better detect recurrence in a group of colon cancer patients whose metastases are hidden. The test, which uses the hormone receptor guanylyl cyclase C as a biomarker, is designed to determine who can benefit from adjuvant chemotherapy.
Adjuvant chemotherapy is used to eradicate whatever occult disease is left after surgery and other treatments.
“This approach can improve prognostic risk stratification and chemotherapeutic allocation for these colon cancer patients,” said Dr. Waldman, who is also chair of the department of pharmacology and experimental therapeutics at the university, and in the release. “With this CURE grant, we can now move a much-needed technology closer to commercialization, meaning closer to patients.”
The CURE grant is for almost $750,000.
Related Articles on Colon Cancer:
Study: Wealthier Patients Choose Colonoscopy Over Home-Based Fecal Occult Blood Test
Florida Hospital Flagler Now Offers Third Eye Colonoscopy
AGA Indentifies Five Treatments Physicians and Patients Should Question
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
